Goosebumps, these 3 articles should help:
3 new CYDY articles:
01) Glaxo’s New Focus After Haleon Spinoff Shines a Light on CytoDyn (OTCMKTS: CYDY) as a Takeover Target
Glaxo’s New Focus After Haleon Spinoff Shines a Light on CytoDyn (OTCMKT...
Chris Sandburg
GSK (NYSE: GSK) has a new mission and that mission is to go after major medical conditions that have no treatmen...
02)
OTC Stocks With 10X Potential: RLBD, CYDY, MRMD, EVIO, BLLB, MJNA, CYBL - Top News Guide
OTC Stocks With 10X Potential: RLBD, CYDY, MRMD, EVIO, BLLB, MJNA, CYBL ...
Jeremiah Abramson
The most important aspect of successful investors lies in identifying stocks before they move upwards strongly. ...
03) from yesterday 7/20/2022
"An experimental antibody made in the lab can completely protect non-human primates from contracting simian-type HIV, according to a new study published in the academic journal Nature Communications.
"Our findings suggest that the monoclonal antibody leronlimab may be a new weapon in the fight against the HIV epidemic," said the study's principal investigator and the paper's co-corresponding author, Jonah Sacha, Ph.D., a professor at Oregon Health Sciences University, inaugural at the Oregon National Primate Center and the Vaccine and Gene Therapy Institute
The results of this study will inform future human clinical trials to evaluate the monoclonal antibody leronlimab as a potential HIV pre-exposure prophylaxis (PrEP) to prevent HIV infection in humans.
“We basically have a tool that mimics the genetic mutation of CCR5 that made some people immune to infection and to some extent cured 2 HIV cases. The results of preclinical studies targeting the HIV co-receptor CCR5 have Breakthrough potential," said Liomwa Ndhlovu, MD, another co-corresponding author and professor of immunology at Weill Cornell Medical College in New York.
The monoclonal antibody, made by Vancouver, Washington-based CytoDyn, blocks HIV from passing through a surface protein called CCR5 by XX immune cells. This injectable drug is already being studied in Phase 3 trials as a potential treatment in combination with standard antiviral drugs.
Currently, CytoDyn is submitting relevant information to the FDA for FDA approval. However, the study began by specifically investigating how to prevent HIV infection.
Some PrEP drugs are already on the market, but they can cause unwanted side effects, such as liver, heart and bone problems, and some HIV genetic mutations can also make PrEP drugs resistant. Existing PrEP regimens often require frequent use, such as one tablet per day, or must be administered in an outpatient setting. Leronlimab is designed to self-inject XX.
To study the effectiveness of leronlimab as a potential PrEP drug, the research team created three experimental groups of six rhesus monkeys at the Oregon National Primate Research Center in Oregon. Two groups received different doses of leronlimab, while the third group served as a control group and received no experimental drug.
A group of macaques received XX high doses of leronlimab every other week at a dose of 50 mg/kg body weight, at which the macaques were completely protected from simian HIV infection. In contrast, two rhesus monkeys receiving weekly 10 mg/kg doses of XX were infected with HIV, and all rhesus monkeys in the control group were infected. The researchers concluded that part of the protection in the low-dose group may be due to the macaques' immune response to human antibodies.
Caption: Dr. Jonah Sacha
Based on the results of the study, CytoDyn plans to conduct an initial clinical trial next year to study leronlimab as a potential PrEP drug in people. Since mud monkey cells have more surface CCR5 protein than humans, the human dose may be lower than that given in this study.
Meanwhile, Dr. Sacha is already working to make leronlimab easier to use. In August 2020, he received a 5-year, $3 million grant from the National Institutes of Health (NIH) to develop a concentrated, longer-lasting formulation of leronlimab that can be injected every three months. Infrequent injection of XX can increase compliance with drug therapy, thereby improving the effectiveness of the drug.
The research team dedicated the study to Timothy Ray Brown, known as the Berlin Patient, who died on September 29, 2020, the first person to be cured of AIDS, for which Brown is known. While living in Berlin in 2007, Brown underwent a bone marrow transplant to treat his blood cancer. The process eliminated Brown's HIV because the transplanted bone marrow came from a donor with a rare genetic mutation that eliminated the CCR5 gene, the surface protein of HIV XX cells. Dr. Sacha and Brown met and became friends at an AIDS conference in 2015. Brown is also a co-author of the paper because he inspired the scientists working on the research.
Source: Red Maple Bay
Disclaimer: This official account is for public health publicity and is not for commercial purposes. Some materials come from the Internet. If any text, pictures, videos or other content involves infringement or violation, please contact us to delete and modify it, thank you!"
3 new CYDY articles:
01) Glaxo’s New Focus After Haleon Spinoff Shines a Light on CytoDyn (OTCMKTS: CYDY) as a Takeover Target
Glaxo’s New Focus After Haleon Spinoff Shines a Light on CytoDyn (OTCMKT...
Chris Sandburg
GSK (NYSE: GSK) has a new mission and that mission is to go after major medical conditions that have no treatmen...
02)
OTC Stocks With 10X Potential: RLBD, CYDY, MRMD, EVIO, BLLB, MJNA, CYBL - Top News Guide
OTC Stocks With 10X Potential: RLBD, CYDY, MRMD, EVIO, BLLB, MJNA, CYBL ...
Jeremiah Abramson
The most important aspect of successful investors lies in identifying stocks before they move upwards strongly. ...
03) from yesterday 7/20/2022
"An experimental antibody made in the lab can completely protect non-human primates from contracting simian-type HIV, according to a new study published in the academic journal Nature Communications.
"Our findings suggest that the monoclonal antibody leronlimab may be a new weapon in the fight against the HIV epidemic," said the study's principal investigator and the paper's co-corresponding author, Jonah Sacha, Ph.D., a professor at Oregon Health Sciences University, inaugural at the Oregon National Primate Center and the Vaccine and Gene Therapy Institute
The results of this study will inform future human clinical trials to evaluate the monoclonal antibody leronlimab as a potential HIV pre-exposure prophylaxis (PrEP) to prevent HIV infection in humans.
“We basically have a tool that mimics the genetic mutation of CCR5 that made some people immune to infection and to some extent cured 2 HIV cases. The results of preclinical studies targeting the HIV co-receptor CCR5 have Breakthrough potential," said Liomwa Ndhlovu, MD, another co-corresponding author and professor of immunology at Weill Cornell Medical College in New York.
The monoclonal antibody, made by Vancouver, Washington-based CytoDyn, blocks HIV from passing through a surface protein called CCR5 by XX immune cells. This injectable drug is already being studied in Phase 3 trials as a potential treatment in combination with standard antiviral drugs.
Currently, CytoDyn is submitting relevant information to the FDA for FDA approval. However, the study began by specifically investigating how to prevent HIV infection.
Some PrEP drugs are already on the market, but they can cause unwanted side effects, such as liver, heart and bone problems, and some HIV genetic mutations can also make PrEP drugs resistant. Existing PrEP regimens often require frequent use, such as one tablet per day, or must be administered in an outpatient setting. Leronlimab is designed to self-inject XX.
To study the effectiveness of leronlimab as a potential PrEP drug, the research team created three experimental groups of six rhesus monkeys at the Oregon National Primate Research Center in Oregon. Two groups received different doses of leronlimab, while the third group served as a control group and received no experimental drug.
A group of macaques received XX high doses of leronlimab every other week at a dose of 50 mg/kg body weight, at which the macaques were completely protected from simian HIV infection. In contrast, two rhesus monkeys receiving weekly 10 mg/kg doses of XX were infected with HIV, and all rhesus monkeys in the control group were infected. The researchers concluded that part of the protection in the low-dose group may be due to the macaques' immune response to human antibodies.
Caption: Dr. Jonah Sacha
Based on the results of the study, CytoDyn plans to conduct an initial clinical trial next year to study leronlimab as a potential PrEP drug in people. Since mud monkey cells have more surface CCR5 protein than humans, the human dose may be lower than that given in this study.
Meanwhile, Dr. Sacha is already working to make leronlimab easier to use. In August 2020, he received a 5-year, $3 million grant from the National Institutes of Health (NIH) to develop a concentrated, longer-lasting formulation of leronlimab that can be injected every three months. Infrequent injection of XX can increase compliance with drug therapy, thereby improving the effectiveness of the drug.
The research team dedicated the study to Timothy Ray Brown, known as the Berlin Patient, who died on September 29, 2020, the first person to be cured of AIDS, for which Brown is known. While living in Berlin in 2007, Brown underwent a bone marrow transplant to treat his blood cancer. The process eliminated Brown's HIV because the transplanted bone marrow came from a donor with a rare genetic mutation that eliminated the CCR5 gene, the surface protein of HIV XX cells. Dr. Sacha and Brown met and became friends at an AIDS conference in 2015. Brown is also a co-author of the paper because he inspired the scientists working on the research.
Source: Red Maple Bay
Disclaimer: This official account is for public health publicity and is not for commercial purposes. Some materials come from the Internet. If any text, pictures, videos or other content involves infringement or violation, please contact us to delete and modify it, thank you!"
11
